Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 04/24/25
Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings EstimatesInvestors Business Daily • 04/24/25
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue EstimatesZacks Investment Research • 04/24/25
Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year GuidanceBarrons • 04/24/25
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug salesReuters • 04/24/25
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffsCNBC • 04/24/25
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock SlidesBenzinga • 04/23/25
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 TestInvestors Business Daily • 04/22/25
Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophreniaReuters • 04/22/25
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with SchizophreniaBusiness Wire • 04/22/25
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?Zacks Investment Research • 04/22/25
Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For RecessionSeeking Alpha • 04/22/25
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 04/18/25
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs24/7 Wall Street • 04/18/25
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and ContraindicationsBusiness Wire • 04/18/25
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/17/25
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTBusiness Wire • 04/16/25
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?Zacks Investment Research • 04/16/25
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With ItInvestors Business Daily • 04/14/25